Lose weight in Spring Festival? Lilly GIP / GLP-1 double target agonist approved for obesity clinical trial in China
-
Last Update: 2020-01-23
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
On January 21, Lilly's tirzepatide injection obtained the implicit clinical license in China for the long-term weight management of overweight or obese patients This is the second tacit clinical license approved for the drug in China, after the drug has been approved for clinical trials of type 2 diabetes in China Tirzepatide is a double agonist of gastric inhibitory peptide (GIP) / glucagon like peptide-1 (GLP-1) receptor A phase IIB clinical study showed that tirzepatide can also reduce the weight of patients with type 2 diabetes while significantly improving their blood sugar levels Six month data showed that tirzepatide could reduce HbA1c level of type 2 diabetes mellitus by 2.4% on average and lose 11.3kg (12.7%) of body weight Tirzepatide not only has a significant therapeutic effect on type 2 diabetes and obesity, but also has a certain therapeutic potential for nonalcoholic steatohepatitis In its 2019 report, evaluatepharma, a well-known investor, listed Lilly as one of the most valuable projects.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.